Skip to main content

Table 2 Antimicrobial prophylaxis received versus ciprofloxacin resistance status

From: Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial

Drug received

N = 510

Ciprofloxacin-susceptible

430, (84.3%)

Ciprofloxacin-resistant

80, (16.3%)

Amikacin

0

2 (2.5)

Aztreonam

0

1 (1.2)

Bactrim

0

23 (28.8)

Bactrim + Gentamicin

0

1(1.2)

Bactrim + Meropenem

0

1 (1.2)

Ceftriaxone

0

3 (3.8)

Cefuroxime

0

38 (47.5)

Ciprofloxacin

406 (94.4)

0

Ciprofloxacin + Amoxicillin

3 (0.7)

0

Ciprofloxacin + Gentamicin

21 (4.9)

0

Ertapenem

0

4 (5.0)

Gentamicin

0

7 (8.8)